Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamaophthalmol.2022.1554 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transient Bacillary Layer Detachment During the Disease Course of Primary Vitreoretinal Lymphoma.
Ocul Immunol Inflamm
June 2024
Ophthalmology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Purpose: To report the clinical course and the retinal imaging features of a case of cytology-proven primary vitreoretinal lymphoma (PVRL) presenting with a transient bacillary layer detachment (BALAD) during the disease course.
Methods: Observational case report.
Results: A 50 year-old woman was referred to us with a 2-month history of vitritis in both eyes, poorly responding to oral prednisolone.
Unlabelled: Primary thyroid tuberculosis is an extremely rare extrapulmonary involvement by the causative agent, . Its rarity and resemblance to thyroid malignancy led to unnecessary aggressive operative interventions.
Case Presentation: A 54-year-old female presented with recent onset dysphagia and foreign body sensation in the throat for 3 months, and anterior neck swelling since last 10 years.
Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate.
BMC Ophthalmol
September 2022
Department of Ophthalmology, Eye and ENT Hospital, Fudan University, 83 Fenyang Road, Shanghai, 200031, China.
Background: To identify retinal changes using spectral-domain optical coherence tomography (SD-OCT) and ultra-widefield images in eyes with primary vitreoretinal lymphoma (PVRL) during intravitreal methotrexate (MTX) treatment. METHODS: This study retrospectively reviewed 111 eyes of 58 patients with vitreous cytology-proven confirmed PVRL, who received intravitreal injections of MTX.
Results: At the initial visit, the OCT manifestations included vitreous cells (105 eyes, 94.
Cytology-Proven Primary Vitreoretinal Lymphoma in a Patient With Paraneoplastic Cloudy Vitelliform Submaculopathy.
JAMA Ophthalmol
July 2022
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
Study protocol of a phase 1 clinical trial establishing the safety of intrapleural administration of liposomal curcumin: curcumin as a palliative treatment for malignant pleural effusion (IPAL-MPE).
BMJ Open
March 2021
Anatomical Pathology, Flinders University, Bedford Park, South Australia, Australia.
Introduction: This is a phase 1, open-label, single-centre, uncontrolled, dose-escalation study to evaluate the feasibility, tolerability and pharmacokinetic profiles of a single dose of liposomal curcumin, administered via an existing tunnelled indwelling pleural catheter (TIPC) directly to the tumour site in individuals with diagnoses of malignant pleural effusion. Primarily, we aim to determine a maximum tolerated dose of liposomal curcumin administered via this method.
Methods And Analysis: We will use a 3+3 expanded cohort for predefined dose-escalation levels or until a predefined number of dose-limiting toxicities are reached.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!